Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study

A. M. Pellicelli, V. Pace Palitti, P. Vignally, F. Ceccherini-Silberstein, M. Siciliano, V. Giannelli, A. Moretti, P. Tarquini, G. Scifo, V. Messina, A. Ascione, A. Izzi, M. Marignani, C. D'Ambrosio, L. Fondacaro, G. M. Ettorre, P. Ialongo, R. Sacco, C. F. Perno, G. BarbariniCLEO Group

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND & AIMS: The proportion of HCV-infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real-world efficacy and safety of the combination of sofosbuvir (SOF) and simeprevir (SMV) plus a flat dose of 800 mg/d ribavirin (RBV) in elderly patients with cirrhosis compared to younger patients. METHODS: Retrospective observational multicentre real-life investigation study of SOF/SMV/RBV for a duration of 12 weeks in HCV genotype 1-infected patients with cirrhosis. RESULTS: Of the 270 patients enrolled in this study, with compensated cirrhosis, 133 (49.2%) were >/=65 years of age. Sustained virological response at 12 weeks (SVR12) was achieved by 94.2% (129/137) of those aged /=65 years. Diabetes was the most common comorbidity in patients >/=65 years compared to younger patients (26.3% vs 12.4% P
Original languageEnglish
Pages (from-to)653-661
Number of pages9
JournalLiver International
Volume37
Issue number5
DOIs
Publication statusPublished - May 1 2017

Keywords

  • cirrhosis
  • elderly
  • genotype 1
  • hepatitis C
  • simeprevir
  • sofosbuvir

Fingerprint Dive into the research topics of 'Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study'. Together they form a unique fingerprint.

Cite this